Short answer: for a first-in-human medical device study at a site in the City of Buenos Aires, I plan on about five to six months from a complete ANMAT submission to first patient. The site’s ethics opinion (about a month) and the hospital’s research committee sign-off have to go into that submission, so they come first. Counted from the first ethics filing, that is roughly six to seven months. If your board needs a first patient within a quarter, Argentina is usually not the first country I would look at.
I get this question almost every week from US device teams who have heard good things about Argentine investigators, and they are right about the investigators. What they often underestimate is the order of the steps. Here is the calendar I actually use, and when I steer a sponsor somewhere else.
Why the ethics committee comes before ANMAT
In several countries, ethics and regulatory reviews can run in parallel. For a Buenos Aires device study, I treat them as sequential. The ANMAT submission package for a clinical study is expected to include the ethics committee’s approval and the institution’s authorization, so a file sent without them is not complete, and an incomplete file does not start any useful clock.
That gives a simple sequence:
- Site selection and contract framework. Pick the site, agree the budget structure and the clinical trial agreement terms, and confirm the investigator’s availability.
- Ethics committee submission. Protocol, investigator’s brochure, informed consent in Argentine Spanish, insurance certificate, and the investigator’s documents. Plan on about a month to an opinion, more if there is a round of questions.
- Hospital research committee or institutional authorization. Many Buenos Aires hospitals have their own research or teaching committee that signs off separately from ethics.
- ANMAT submission. With the approvals in hand, file the complete package. From there, my planning figure is five to six months to first patient, which covers agency review, any questions, import of the investigational device, and site initiation.
Add those up and a work order signed in December points to a first patient around the middle of the following year at the earliest, and more likely the third quarter. Any round of agency questions adds time on top.
City of Buenos Aires versus Buenos Aires Province
“Buenos Aires” is two jurisdictions, and the difference matters. The City of Buenos Aires has its own law on research with human subjects (Ley 3301) and its own ethics oversight framework. Sites in Buenos Aires Province, which surrounds the City, add a provincial registration step on top of the national ANMAT process. A province site can be the right choice for patient volume or investigator fit, but budget extra weeks for that step and confirm the provincial requirements with the site before you lock the calendar.
What usually slows a Buenos Aires start
- Incomplete first files. Missing translations, an insurance certificate that does not match the protocol version, or investigator documents that are out of date. Each one sends you back to the start of a queue.
- Protocol amendments mid-review. Changing the protocol while ethics or ANMAT is reviewing it usually restarts that review. Freeze the protocol before the first submission.
- Device import. The investigational device cannot clear customs before the study authorization, so the import paperwork and logistics have to be ready the day approval arrives.
- Agency questions. A round of questions is common for a first-in-human device. Plan for at least one.
When I steer sponsors to another country
If a first patient within one quarter is the priority, I look first at Panama, Costa Rica, Chile or El Salvador. For those, my planning range is 30 to 60 days for ethics and regulatory review after a complete file. Even then, I tell sponsors to treat a first patient about three months out as a stretch and four to five months as the safer range, because site contracts, insurance and device import still take time.
Guatemala is a different trade-off: a population of almost 19 million and a longer path, about 120 days for review in my planning.
None of this makes Argentina a bad choice. For a study where investigator depth, a specific clinical specialty or patient volume matters more than the first-patient date, Buenos Aires is often worth the extra months. The mistake is choosing Argentina for speed and then building a fundraising milestone on a first-patient date the calendar cannot support.
How to decide
I ask sponsors three questions before recommending a country:
- What is driving the first-patient date, and what slips if it is three months later?
- Is the study better served by one country with two or three sites, or by a fast first country followed by a second for enrollment?
- Is the protocol truly frozen, and is the device ready to ship with its documentation?
If the date is fixed and the protocol is frozen, start with one of the faster countries and add Argentina as a second country if enrollment needs it. If the date has room and investigator expertise is the deciding factor, start the Buenos Aires ethics filing as early as possible, because every week before that filing is a week added to first patient.
The bottom line
For a City of Buenos Aires device first-in-human study, plan on about six to seven months from the first ethics filing to first patient, longer for a Buenos Aires Province site or if the agency asks questions. If you need a first patient sooner, look at Panama, Costa Rica, Chile or El Salvador first.
A note on our own earlier numbers: our August 2026 ANMAT clinical trial requirements guide gives a median of about five months from signed agreement to first patient for a Buenos Aires-only study and describes ethics and regulatory filings running in parallel. Based on recent device start-ups, I now plan more conservatively and treat the ethics opinion and institutional sign-off as inputs to a complete ANMAT file. If your plan was built on the shorter figure, rebuild it on this one.
For the document checklist and the province-by-province detail, see that guide and our knowledge base. bioaccess® runs first-in-human and early feasibility device studies across Latin America and can help you compare calendars country by country.
Julio G. Martinez-Clark is CEO of bioaccess®, a contract research organization focused on first-in-human and early feasibility medical device studies in Latin America.
Sources and notes
- Timelines are bioaccess® planning figures from recent study start-ups, not official agency clocks; they assume a complete file and can change with agency workload.
- ANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica), clinical study authorization requirements.
- Ley 3301 de la Ciudad Autónoma de Buenos Aires, protection of the rights of research subjects.